There are currently 321 active clinical trials seeking participants for Obesity research studies. The states with the highest number of trials for Obesity participants are California, Texas, Florida and North Carolina.
A Research Study on How a Dose of NNC0662-0419 Works in Japanese, Chinese and Non-Asian Participants Living With Overweight or Obesity
NCT07101783
Recruiting
The study is testing the new medicine NNC0662-0419 in people living with overweight or obesity. The purpose of the study is to look into the amount of the new medicine NNC0662-0419 in participants blood after one dose. And also look into how safe and how well the study medicine is tolerated in people living with overweight or obesity. NNC0662-0419 is a new medicine which cannot be prescribed by doctors. NNC0662-0419 is currently being tested in humans and the dose participants will receive has b... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
08/06/2025
Locations: Altasciences Clinical LA, Inc., Cypress, California
Conditions: Overweight, Obesity
Register for Updates
Concentration of n-3 PUFA Monohydroxylated Derivatives in Male Adults With Obesity After n-3 PUFA Supplementation.
NCT06991296
Recruiting
The goal of this clinical trial is to learn if daily supplementation with SPM Active® can increase omega 3 polyunsaturated fatty acid derivatives and improve well-being in male adults with obesity. The main questions it aims to answer are: Does 2 g/day of SPM Active® for 12 weeks increase plasma levels of 14-hydroxydocosahexaenoic (HDHA), 17-HDHA, and 18-hydroxy eicosapentaenoic acid (HEPE)? Does 2 g/day of SPM Active® for 12 weeks improve self-reported burnout, life satisfaction, and sleep qu... Read More
Gender:
MALE
Ages:
Between 45 years and 60 years
Trial Updated:
08/06/2025
Locations: UNC Nutrition Research Institute, Kannapolis, North Carolina
Conditions: Obesity
Register for Updates
A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity
NCT06916065
Recruiting
The purpose of this study is to evaluate how well eloralintide and eloralintide with tirzepatide is tolerated and what side effects may occur in participants with overweight or obesity. The study drug will be administered subcutaneously (SC) (under the skin). Blood tests will be performed to check how much eloralintide and eloralintide with tirzepatide get into the bloodstream and how long it takes the body to eliminate it. There will be 6 cohorts. The study will last up to approximately 26 wee... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/06/2025
Locations: Anaheim Clinical Trials, LLC, Anaheim, California +2 locations
Conditions: Overweight, Obesity
Register for Updates
Mother-Baby Study - Observational
NCT06039878
Recruiting
The rate of weight gain in the first year of life is risk factor for future obesity. The study will test (1) a model of l mechanisms underlying the development of emotion, attachment, and nutritive intake; and (2) the association with maternal feeding behavior, child eating behavior, dietary intake, and adiposity.
Gender:
ALL
Ages:
0 days and above
Trial Updated:
08/05/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Obesity, Childhood, Obesity
Register for Updates
Pilot Study of Isocaloric Time Restricted Eating on Ketone Metabolism and Immunoregulation
NCT06169137
Recruiting
Background: Time restricted eating (TRE) is a form of fasting in which a person eats only during a set window of time, which is usually between 4 and 10 hours each day. Researchers want to know more about how TRE may affect health. Objective: To learn how TRE affects women with different body sizes. Eligibility: Healthy women aged 18 to 50 years. Design: Participants will have 2 visits: 1 screening visit and one 5-day stay in the clinic. Participants will fast before both visits. They wi... Read More
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
08/05/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Obesity, Body Weight
Register for Updates
Youth-Onset Type 2 Diabetes and Heart Disease: The Young at Heart Prospective Cohort Study
NCT06730113
Recruiting
Background: Type 2 diabetes is a disease that affects blood sugar levels. Complications can include heart and blood vessel (vascular) diseases. Rates of type 2 diabetes have tripled in children and young adults over the last 40 years. Vascular diseases are also increasing in young people. Objective: To learn more about factors, including type 2 diabetes, that may cause vascular disease in young people. Eligibility: People aged 12 to 25 years who (1) have type 2 diabetes; (2) are overweight... Read More
Gender:
ALL
Ages:
Between 12 years and 25 years
Trial Updated:
08/05/2025
Locations: Children's National Hospital (CNH), Washington, District of Columbia +1 locations
Conditions: Obesity, Type 2 Diabetes
Register for Updates
Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate
NCT06044935
Recruiting
Background: At least 30% of Americans have fatty liver disease. This means that they store too much fat in the liver. At the moment lifestyle changes are the only way to treat this problem. Objective: To test how (1) a low-carbohydrate diet and (2) a supplement called nicotinamide riboside (NR) affect how a person s body uses dietary fat. Eligibility: Men aged 18 to 65 and women aged 18 to 50 who are healthy volunteers with a body mass index (height to weight ratio) of 25 or more. Adults wi... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/05/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Overweight, Obesity
Register for Updates
Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist
NCT06851858
Recruiting
This Phase II study is a randomized, parallel group, double blinded, placebo-controlled, multicenter to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and type 2 diabetes on stable GLP-1 RA therapy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/04/2025
Locations: Research Site, Birmingham, Alabama +17 locations
Conditions: Endocrinology, Diabetes, Type II, Obesity
Register for Updates
Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia
NCT04839614
Recruiting
To assess the feasibility of an expedited referral process for the obese endometrial cancer or EIN patient from her gynecologic oncologist to the Brigham Center for Metabolic and Bariatric Surgery (CMBS) in order to undergo concurrent weight loss surgery and hysterectomy within 8 weeks of first appointment with a gynecologic oncologist (or 12 weeks for EIN patients).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Endometrial Carcinoma, Obesity, EIN, Endometrial Intraepithelial Neoplasia, Endometrial Cancer Stage I
Register for Updates
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
NCT06098079
Recruiting
A randomized, double-blinded, placebo controlled study intended to capture cardiovascular outcomes during real-world use of naltrexone/bupropion (NB).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2025
Locations: Accel Research Sites Network, Birmingham, Alabama +133 locations
Conditions: Obesity
Register for Updates
Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
NCT06138821
Recruiting
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. While weight loss through lifestyle modification is the standard treatment, most patients regain weight limiting ultimate improvement in liver disease. On the other end of the spectrum, bariatric surgery has shown promise in the treatment of MASLD/metabolic dysfunction-associated steatohepatitis (MASH) due to its efficacy in inducing weight loss. Nevertheless, its adoption has been... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Obesity, Liver Diseases, Liver Fibrosis, Liver Fat, Weight Loss, Insulin Resistance, Insulin Sensitivity, Insulin Sensitivity/Resistance, Diabetes, Diabetes Mellitus, Type 2, NASH With Fibrosis, Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non-alcoholic Steatohepatitis, Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, MASLD, MASH, Metabolic Disease
Register for Updates
Children s Growth and Behavior Study
NCT02390765
Recruiting
Background: - Studies show that many factors affect children's eating behavior and health. These include sleep, mood, thinking skills, and genetics. Studying children over time may identify children at higher risk for eating-related health concerns. Objective: - To understand how genes and environment influence eating behavior and health over time. Eligibility: - Children ages 8-17 in good general health. Design: * Screening visit 1: Medical history, physical exam, body measurements, and... Read More
Gender:
ALL
Ages:
Between 8 years and 100 years
Trial Updated:
07/31/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Obesity, Eating Behaviors, Healthy Volunteers
Register for Updates